

CITATION REPORT

List of articles citing

Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases

DOI: 10.1136/annrheumdis-2017-211937
Annals of the Rheumatic Diseases, 2018, 77, 165-174.

Source: <https://exaly.com/paper-pdf/69610813/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
152	Therapy: Biosimilars in rheumatology - why, how and when in 2017. 2017 , 13, 701-703		4
151	[Pharmacological treatment of rheumatoid arthritis and its comorbidities]. 2018 , 59, 341-351		2
150	Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes. <i>Drugs</i> , 2018 , 78, 463-478	12.1	123
149	Les biosimilaires: une opportunit�Position de la Soci�fran�aise de rhumatologie (SFR) et du club rhumatismes et inflammation (CRI). 2018 , 85, 319-323		
148	Immunogenicity Assessment of Biosimilars. 2018 , 32, 103-121		6
147	The confidence of rheumatologists about switching to biosimilars for their patients. 2018 , 85, 507-509		10
146	Current and future perspectives in the management of juvenile idiopathic arthritis. 2018 , 2, 360-370		21
145	[Revised version of the statement by the DGRh on biosimilars-update 2017]. <i>Zeitschrift Fur Rheumatologie</i> , 2018 , 77, 81-90	1.9	6
144	Rheumatoid arthritis. 2018 , 4, 18001		750
143	ABP 501 for the treatment of rheumatoid arthritis. 2018 , 18, 317-322		12
142	Biosimilars: An opportunity. Position statement of the French Rheumatology Society (SFR) and Inflammatory Rheumatic Disease Club (CRI). 2018 , 85, 399-402		11
141	GP2015 as a promising therapy for rheumatoid arthritis. 2018 , 18, 477-481		2
140	Treatment of chronic inflammatory rheumatism by biotherapy in Gabon: eligibility and follow-up of the first 8 patients in sub-Saharan Africa. 2018 , 28, 197-200		1
139	Standardisation of synovial biopsy analyses in rheumatic diseases: a consensus of the EULAR Synovitis and OMERACT Synovial Tissue Biopsy Groups. 2018 , 20, 265		18
138	Biosimilar switching - current state of knowledge. 2018 , 56, 234-242		24
137	Diagnosis and Management of Rheumatoid Arthritis: A Review. 2018 , 320, 1360-1372		596
136	Golimumab in the treatment of psoriatic arthritis. <i>Expert Review of Clinical Immunology</i> , 2018 , 14, 893-898	3.1	3

135	Nocebos in rheumatology: emerging concepts and their implications for clinical practice. 2018 , 14, 727-740		47
134	Focus on biosimilar etanercept - bioequivalence and interchangeability. 2018 , 12, 87-95		11
133	Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction. 2018 , 41, 1013-1022		25
132	[S2e guideline: treatment of rheumatoid arthritis with disease-modifying drugs]. <i>Zeitschrift Fur Rheumatologie</i> , 2018 , 77, 35-53	1.9	41
131	Does a mandatory non-medical switch from originator to biosimilar infliximab lead to increased use of outpatient healthcare resources? A register-based study in patients with inflammatory arthritis. <i>RMD Open</i> , 2018 , 4, e000710	5.9	16
130	Acceptance rate and sociological factors involved in the switch from originator to biosimilar etanercept (SB4). 2019 , 48, 927-932		36
129	Beeinflusst von Quoten und Genen. 2019 , 22, 12-14		
128	Challenges in Post-marketing Studies of Biological Drugs in the Era of Biosimilars: A Report of the International Society for Pharmacoepidemiology 2019 Mid-Year Meeting in Rome, Italy. <i>BioDrugs</i> , 2019 , 33, 345-352	7.9	5
127	Maintained Clinical Remission in Ankylosing Spondylitis Patients Switched from Reference Infliximab to Its Biosimilar: An 18-Month Comparative Open-Label Study. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	7
126	Does Triple Conventional Synthetic Disease-Modifying Antirheumatic Drug Therapy Improve upon Methotrexate as the Initial Treatment of Choice for a Rheumatoid Arthritis Patient?. 2019 , 45, 315-324		1
125	Role of biological agents in treatment of rheumatoid arthritis. 2019 , 150, 104497		23
124	Biosimilaires . Commentaire de l'article : « Les biosimilaires : une opportunit�Position de la Soci� Fran�aise de Rhumatologie (SFR) et du Club Rhumatismes et Inflammation (CRI) ». 2019 , 86, 543-544		
123	Biosimilars vs originators: Are they the same?. 2019 , 18, 102404		3
122	Management of rheumatoid arthritis: 2019 updated consensus recommendations from the Hong Kong Society of Rheumatology. 2019 , 38, 3331-3350		11
121	Same but different? A thematic analysis on adalimumab biosimilar switching among patients with juvenile idiopathic arthritis. 2019 , 17, 67		5
120	Information et perception des patients au sujet des biosimilaires en rhumatologie. 2019 , 86, 591-596		
119	Era of biosimilars in rheumatology: reshaping the healthcare environment. <i>RMD Open</i> , 2019 , 5, e000900	5.9	39
118	Are There Benefits and Risks to Biosimilars from a Patient Perspective?. 2019 , 45, 465-476		3

117	Major Challenges in Rheumatology: Will We Ever Treat Smarter, Instead of Just Harder?. <i>Frontiers in Medicine</i> , 2019 , 6, 144	4.9	6
116	Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial. <i>Rheumatology</i> , 2019 , 58, 2193-2202	3.9	22
115	Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study. 2019 , 21, 122		5
114	Switching to biosimilars: current perspectives in immune-mediated inflammatory diseases. 2019 , 19, 1001-1014		12
113	Biosimilars in the Americas: the future by consensus. 2019 , 38, 1497-1499		3
112	Patients' information and perspectives on biosimilars in rheumatology: A French nation-wide survey. 2019 , 86, 491-496		19
111	Patient Perspectives on Switching from Infliximab to Infliximab-dyyb in Patients with Rheumatologic Diseases in the United States. 2019 , 1, 52-57		5
110	Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities?. <i>Frontiers in Pharmacology</i> , 2019 , 10, 279	5.6	57
109	Rheumatology in Poland. 2019 , 39, 757-767		5
108	Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients. 2019 , 49, 1181-1187		31
107	Systemic rheumatic diseases: From biological agents to small molecules. 2019 , 18, 583-592		45
106	Infliximab biosimilar for treating neurosarcoidosis: tolerance and efficacy in a retrospective study including switch from the originator and initiation of treatment. 2019 , 266, 1073-1078		9
105	AB0375 HYPOGAMMAGLOBULINEMIA AFTER RITUXIMAB TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS IS NOT RARE AND IS ASSOCIATED WITH BETTER RESPONSE. 2019 ,		
104	Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs? A Danish register-based study of patients with inflammatory arthritis. <i>RMD Open</i> , 2019 , 5, e001016	5.9	10
103	Observational study of inflammatory arthritis treatment by etanercept originator switched to an etanercept biosimilar. 2019 , 57, 257-263		7
102	The Clinical Implications of Nocebo Effects for Biosimilar Therapy. <i>Frontiers in Pharmacology</i> , 2019 , 10, 1372	5.6	30
101	Les substitutions multiples du produit de référence Éanercept vers son biosimilaire et inversement n'affectent pas l'activité de la maladie ou le taux de rétention de l'Éanercept après 24 mois : Étude de cohorte avec groupe témoin historique. 2019 , 86, 644-646		
100	Repeated switches between reference product etanercept and biosimilar do not affect disease activity or retention rate of etanercept over 24 months - a cohort study with historical controls. 2019 , 86, 529-530		5

99	To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 192-200	2.4	71
98	Biosimilars: complements and comments on the recent statement of the SFR and CRI. Comment on: "Biosimilars: An opportunity. Position statement of the French Rheumatology Society (SFR) and Inflammatory Rheumatic Disease Club (CRI)." Schaeferbeke et al. <i>Joint Bone Spine</i> 2018,95:399-402. 2019 , 86, 287-288		
97	Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab. 2019 , 49, 31-40		48
96	Etanercept biosimilar SB-4. 2019 , 19, 173-179		17
95	[Biosimilars in France, to understand the stakes in order to use them well]. 2019 , 40, 5-8		2
94	Confiance des rhumatologues quant au passage à un biosimilaire. 2019 , 86, 115-118		
93	Additional response to the correspondence: 'Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?' by Cantini and Bennuci. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, e26	2.4	3
92	Additional comment to: 'Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?' by Scherlinger and Schaeferbeke. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, e25	2.4	4
91	Response to: 'Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?' by Cantini and Bennuci. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, e24	2.4	2
90	Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, e23	2.4	22
89	Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, e13	2.4	6
88	Response to: 'Mandatory, cost-driven switching from originator etanercept to its biosimilar SB: possible fallout on non-medical switching' by Cantini and Bennuci. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, e14	2.4	2
87	'To switch or not to switch': the missing piece in the puzzle of biosimilar literature?. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, e36	2.4	6
86	Long-term follow-up after switching from originator infliximab to its biosimilar CT-P13: the weight of placebo effect. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, e11	2.4	12
85	Clinical trial and 'real-world' data support switching from a bio-originator to its biosimilar. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, e44	2.4	3
84	Effectiveness of etanercept biosimilar SB4 in maintaining low disease activity in patients with psoriatic arthritis switched from etanercept originator: an open-label one year study. 2020 , 31, 687-691		6
83	[Biosimilars and the placebo effect]. <i>Zeitschrift Fur Rheumatologie</i> , 2020 , 79, 267-275	1.9	1
82	Singapore chapter of rheumatologists' updated consensus statement on the eligibility for government subsidization of biologic and targeted therapy for the treatment of psoriatic arthritis. 2020 , 23, 153-164		0

81	One-year results after transitioning from etanercept originator to biosimilar in a setting promoting shared decision-making in rheumatology. 2020 , 4, rkaa042		7
80	Biosimilars, a new era in rheumatology in Spain. 2020 , 16, 131-132		1
79	Efficacy and safety of a single switch from etanercept originator to etanercept biosimilar in a cohort of inflammatory arthritis. 2020 , 10, 16178		5
78	Retention Rate and Efficacy of the Biosimilar CT-P13 Versus Reference Infliximab in Patients with Ankylosing Spondylitis: A Propensity Score-Matched Analysis from the Korean College of Rheumatology Biologics Registry. <i>BioDrugs</i> , 2020 , 34, 529-539	7.9	4
77	A NEVER-ENDING STORY OF RHEUMATOID ARTHRITIS. 2020 , 10-17		
76	Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study. <i>BioDrugs</i> , 2020 , 34, 809-823	7.9	10
75	Preconceived notions about biosimilars-a French experience. 2020 , 39, 2251-2254		
74	DMARDs-Gut Microbiota Feedback: Implications in the Response to Therapy. 2020 , 10,		4
73	Stellungnahme der Gesellschaft für Kinder- und Jugendrheumatologie bezüglich der Verwendung von Biosimilars. 2020 , 40, 40-43		
72	Biosimilars und der Nocebo-Effekt. 2020 , 19, 179-189		
71	The Law and Ethics of Switching from Biologic to Biosimilar in Canada. 2020 , 3, 228-233		6
70	Biosimilars, a new era in rheumatology in Spain. 2020 , 16, 131-132		0
69	Greetings from the editor 2020. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1-2	2.4	12
68	Hospital contacts due to hepatobiliary adverse events in >5000 patients with inflammatory joint disease treated with originator or biosimilar etanercept (SB4): an observational nationwide study applying linkage between DANBIO and national registries. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 846-848	2.4	2
67	Management of ANCA associated vasculitis. 2020 , 368, m421		29
66	Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial. <i>BioDrugs</i> , 2020 , 34, 381-393	7.9	8
65	Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease. 2020 , 14, 1-11		4
64	An Opportunity Missed: Biosimilars in the United States. 2020 , 72, 1046-1048		2

63	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 685-699 ^{3,4}	851
62	Increasing Operational Capacity and Reducing Costs of Rituximab Administration: A Costing Analysis. 2020 , 2, 261-268	5
61	Doctor's aptitude for switching from innovator etanercept to biosimilar etanercept in inflammatory rheumatic diseases: experience from a single French rheumatology tertiary care center. 2021 , 77, 25-33	5
60	Biosimilars in der pädiatrischen Rheumatologie. <i>Springer Reference Medizin</i> , 2021 , 1-6	0
59	Informing Patients about Biosimilar Medicines: The Role of European Patient Associations. 2021 , 14,	9
58	Systematic review and meta-analysis of biosimilar for the treatment of rheumatoid arthritis informing the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis. 2021 , 1-13	1
57	bDMARDs retention rate in the biosimilar era: A real-life monocentric study. 2020 ,	0
56	Expert consensus for in-hospital neurorehabilitation during the COVID-19 pandemic in low- and middle-income countries.. 2021 , 6, 130	1
55	PRACTICAL MANAGEMENT of patients on anti-TNF therapy: Practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI). 2021 , 88, 105174	
54	Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects. <i>RMD Open</i> , 2021 , 7,	5.9 3
53	Policies to Encourage the Use of Biosimilars in European Countries and Their Potential Impact on Pharmaceutical Expenditure. <i>Frontiers in Pharmacology</i> , 2021 , 12, 625296	5.6 8
52	Infliximab Biosimilar CT-P13 Observational Studies for Rheumatoid Arthritis, Inflammatory Bowel Diseases, and Ankylosing Spondylitis: Pooled Analysis of Long-Term Safety and Effectiveness. <i>Advances in Therapy</i> , 2021 , 38, 4366-4387	4.1 2
51	Cost-effectiveness of Anbainuo plus methotrexate compared to conventional disease-modifying antirheumatic drugs for rheumatoid arthritis patients in China. <i>Annals of Translational Medicine</i> , 2021 , 9, 1165	3.2 1
50	[80 milestones in rheumatology from 80 years-IV. 2000-2020]. <i>Zeitschrift Fur Rheumatologie</i> , 2021 , 80, 528-538	1.9
49	An Update Review of Biosimilars of Adalimumab in Psoriasis - Bioequivalence and Interchangeability. <i>Drug Design, Development and Therapy</i> , 2021 , 15, 2987-2998	4.4 2
48	OBSIDIAn - real world evidence of Originator to BioSimilar Drug switch in juvenile idiopathic arthritis. <i>Rheumatology</i> , 2021 ,	3.9 3
47	Ixekizumab: an IL-17A inhibitor for the treatment of axial Spondylarthritis. <i>Expert Review of Clinical Immunology</i> , 2021 , 17, 1059-1071	5.1 0
46	The use of biosimilars as a new approach to the treatment of rheumatoid arthritis. <i>Meditinskiy Sovet</i> , 2021 , 112-121	0.4

45	Yisaipu Provide AS Patients With an Economical Therapeutic Option While Original Biologicals are More Advantageous in the COVID-19 Epidemic Situation. <i>Frontiers in Pharmacology</i> , 2021 , 12, 692768	5.6	0
44	Monitoring the transition of patients on biologics in rheumatoid arthritis: Consensus guidance for pharmacists. <i>Pharmacy Practice</i> , 2021 , 19, 2377	1.8	
43	Study on the alleviation of Fengshi Gutong capsule on rheumatoid arthritis through integrating network pharmacology and experimental exploration. <i>Journal of Ethnopharmacology</i> , 2021 , 280, 114471 ⁵		1
42	Multidisciplinary team intervention to reduce the nocebo effect when switching from the originator infliximab to a biosimilar. <i>RMD Open</i> , 2021 , 7,	5.9	7
41	Biosimilars in pediatric rheumatology and their introduction into routine care. <i>Clinical Immunology</i> , 2020 , 216, 108447	9	4
40	Switching to biosimilars in the treatment of rheumatic diseases. <i>Expert Review of Clinical Immunology</i> , 2018 , 14, 557-571	5.1	4
39	Patient satisfaction survey: substitution of reference etanercept with a biosimilar product. <i>European Journal of Hospital Pharmacy</i> , 2021 , 28, 109-111	1.6	2
38	Recent advances in managing axial spondyloarthritis. <i>F1000Research</i> , 2020 , 9,	3.6	2
37	PROSPECTS FOR ANTI-B-CELL THERAPY IN IMMUNO-INFLAMMATORY RHEUMATIC DISEASES. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 57, 1-40	0.9	10
36	Rheumatoid arthritis: problems of treatment at the present stage. <i>Sovremennaya Revmatologiya</i> , 2018 , 12, 65-70	0.7	2
35	Comparative efficacy and safety of adalimumab biosimilar (BCD-057) and innovator in patients with psoriasis vulgaris. Results of the BCD-057-2/CALYPSO phase III international, multicenter, randomized double-blind clinical trial. <i>Sovremennaya Revmatologiya</i> , 2018 , 12, 71-84	0.7	1
34	Interchangeability and substitution of biosimilars: is health technology assessment (HTA) a tool for decision-making?. <i>Cadernos De Saude Publica</i> , 2019 , 35, e00087219	3.2	1
33	Biosimilars in Rheumatic Diseases: Regulatory Guidelines, Efficacy and Safety Implications in Saudi Arabia. <i>Open Rheumatology Journal</i> , 2018 , 12, 313-322	0.2	4
32	Biosimilars in the management of chronic inflammatory diseases: The Dutch experience. <i>Mediterranean Journal of Rheumatology</i> , 2019 , 30, 76-81	1.4	4
31	Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?. <i>Drugs</i> , 2021 , 81, 1859-1879	1.7	3
30	Biosimilar medicines and patient registries: Expectations, limitations, and opportunities. <i>Acta Medica Martiniana</i> , 2017 , 17, 39-51	0.2	1
29	COMPARATIVE EVALUATION OF THE LONG-TERM EFFICACY AND SAFETY OF THE INFLIXIMAB BIOSIMILAR BCD-055 AND REFERENCE INFLIXIMAB IN PATIENTS WITH ANKYLOSING SPONDYLITIS: RESULTS OF THE INTERNATIONAL MULTICENTER RANDOMIZED DOUBLE-BLIND PHASE III CLINICAL STUDY ASART-2. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2018 , 56, 293-301	0.9	2
28	2018 Position Paper on Biosimilars of the Greek Rheumatology Society and Professional Association of Greek Rheumatologists. <i>Mediterranean Journal of Rheumatology</i> , 2019 , 30, 82-83	1.4	

27	Updated Greek Rheumatology Society Guidelines for the Management of Rheumatoid Arthritis. <i>Mediterranean Journal of Rheumatology</i> , 2020 , 31, 163-171	1.4	0
26	Pharmacovigilance of biosimilars - Why is it different from generics and innovator biologics?. <i>Journal of Postgraduate Medicine</i> , 2020 , 66, 116	0.8	0
25	Rheumatic Diseases and Biosimilars: Evidence about Switch from Originators to Biosimilars in the Real Life.		
24	Stellungnahme der Gesellschaft für Kinder- und Jugendrheumatologie bezüglich der Verwendung von Biosimilars. <i>Kinder- Und Jugendmedizin</i> , 2020 , 20, 322-325	0	
23	Natural and iatrogenic ocular manifestations of rheumatoid arthritis: a systematic review. <i>International Ophthalmology</i> , 2021 , 1	2.2	1
22	The Economic Impact of Originator-to-Biosimilar Non-medical Switching in the Real-World Setting: A Systematic Literature Review. <i>Advances in Therapy</i> , 2021 , 1	4.1	2
21	[Use of biosimilars in the treatment of rheumatoid arthritis : An overview]. <i>Zeitschrift Fur Rheumatologie</i> , 2021 , 1	1.9	
20	Efficacy and Drug Survival after Switching from Etanercept to the Biosimilar SB4: A Real-Life Long-Term Study.. <i>Journal of Clinical Medicine</i> , 2022 , 11,	5.1	0
19	Pharmacokinetics and pharmacodynamics of a proposed tocilizumab biosimilar MSB11456 versus both the US-licensed and EU-approved products: a randomized, double-blind trial.. <i>Expert Review of Clinical Immunology</i> , 2022 ,	5.1	2
18	Regulatory Information and Guidance on Biosimilars and Their Use Across Europe: A Call for Strengthened One Voice Messaging.. <i>Frontiers in Medicine</i> , 2022 , 9, 820755	4.9	1
17	Patients Retransitioning from Biosimilar TNF inhibitor to the Corresponding Originator After Initial Transitioning to the Biosimilar: A Systematic Review. <i>BioDrugs</i> , 2021 , 36, 27	7.9	1
16	Table_1.DOCX. 2019 ,		
15	Knowledge, Attitudes and Practice of Healthcare Providers, Healthcare Regulatory Practitioners and Patients Toward Biosimilars in China: Insights From a Nationwide Survey. <i>Frontiers in Pharmacology</i> , 13,	5.6	0
14	Biosimilars in der pädiatrischen Rheumatologie. <i>Springer Reference Medizin</i> , 2022 , 259-264	0	
13	Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking. <i>Frontiers in Pharmacology</i> , 13,	5.6	1
12	Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies. <i>BioDrugs</i> ,	7.9	2
11	Use of follow-on disease-modifying treatments for multiple sclerosis: Consensus recommendations. 135245852211162		
10	Effectiveness and safety of a biosimilar-to-biosimilar switch of the TNF inhibitor etanercept in patients with chronic inflammatory rheumatic diseases. 2022 , 14, 1759720X2211195		0

- 9 Patients with Ankylosing Spondylitis Can Maintain Clinical and Functional Improvement after Switching from Infliximab Reference Product to Infliximab Biosimilar (REMSIMA): 12 Months Comparative Open-Label Study. 1-6 ○
- 8 Generic MS medications: Reducing costs without compromising safety. 135245852211351 ○
- 7 Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry. **2022**, 8, e002560 ○
- 6 Novel Gut microbiota as new biomarkers to evaluate the therapeutic effect of different DMARDs in Rheumatoid Arthritis. ○
- 5 Continuous effectiveness and safety after a hospital-wide switch to adalimumab biosimilar: An observational study in rheumatoid arthritis patients. **2022**, 10, ○
- 4 Novel Gut microbiota as new biomarkers to evaluate the therapeutic effect of different DMARDs in Rheumatoid Arthritis. ○
- 3 Effectiveness and Persistence in SB4 - and Reference Etanercept-treated Rheumatoid Arthritis Patients in Ordinary Clinical Practice in Norway. ○
- 2 Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study. **2023**, 9, e002898 ○
- 1 Administrative Databases and Diagnostic Therapeutic and Assistance Paths -PDTA- in the Monitoring Treatment of Rheumatoid Arthritis: The Experience of ATS Pavia. Volume 14, 29-38 ○